Evaxion Biotech A/S (NASDAQ:EVAX) traded today at a new 52-week high of $25.04. So far today approximately 2.3 million shares have been exchanged, as compared to an average 30-day volume of 66,000 shares.
Evaxion Biotech AS is an artificial intelligence immunology platform company. It uses proprietary AI technology, engineering expertise, and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market. Its two lead product candidates are EVX-01 and EVX-02, for the treatment of various cancers.
Evaxion Biotech A/S share prices have moved between a 52-week high of $25.04 and a 52-week low of $5.16 and are now trading 241% above that low price at $17.57 per share.
Evaxion Biotech A/S (NASDAQ:EVAX) defies analysts with a current price ($17.57) 65.1% above its average consensus price target of $6.14.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer